These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 15158158

  • 1. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain.
    Arendash GW, Lewis J, Leighty RE, McGowan E, Cracchiolo JR, Hutton M, Garcia MF.
    Brain Res; 2004 Jun 25; 1012(1-2):29-41. PubMed ID: 15158158
    [Abstract] [Full Text] [Related]

  • 2. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging.
    Jensen MT, Mottin MD, Cracchiolo JR, Leighty RE, Arendash GW.
    Neuroscience; 2005 Jun 25; 130(3):667-84. PubMed ID: 15590151
    [Abstract] [Full Text] [Related]

  • 3. Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition.
    Leighty RE, Nilsson LN, Potter H, Costa DA, Low MA, Bales KR, Paul SM, Arendash GW.
    Behav Brain Res; 2004 Aug 12; 153(1):107-21. PubMed ID: 15219712
    [Abstract] [Full Text] [Related]

  • 4. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein.
    Lee KW, Lee SH, Kim H, Song JS, Yang SD, Paik SG, Han PL.
    J Neurosci Res; 2004 May 15; 76(4):572-80. PubMed ID: 15114629
    [Abstract] [Full Text] [Related]

  • 5. A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice.
    Arendash GW, Jensen MT, Salem N, Hussein N, Cracchiolo J, Dickson A, Leighty R, Potter H.
    Neuroscience; 2007 Oct 26; 149(2):286-302. PubMed ID: 17904756
    [Abstract] [Full Text] [Related]

  • 6. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.
    Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G, Arendash GW.
    J Pineal Res; 2009 Aug 26; 47(1):82-96. PubMed ID: 19538338
    [Abstract] [Full Text] [Related]

  • 7. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice.
    Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, Shytle RD, Tan J.
    Brain Res; 2008 Jun 12; 1214():177-87. PubMed ID: 18457818
    [Abstract] [Full Text] [Related]

  • 8. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.
    Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E.
    Science; 2001 Aug 24; 293(5534):1487-91. PubMed ID: 11520987
    [Abstract] [Full Text] [Related]

  • 9. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities.
    Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR.
    Neurobiol Dis; 2005 Apr 24; 18(3):602-17. PubMed ID: 15755686
    [Abstract] [Full Text] [Related]

  • 10. Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer's disease: a multi-electrode array study.
    Chong SA, Benilova I, Shaban H, De Strooper B, Devijver H, Moechars D, Eberle W, Bartic C, Van Leuven F, Callewaert G.
    Neurobiol Dis; 2011 Dec 24; 44(3):284-91. PubMed ID: 21807097
    [Abstract] [Full Text] [Related]

  • 11. Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer's disease in aged mice.
    Kawasumi M, Chiba T, Yamada M, Miyamae-Kaneko M, Matsuoka M, Nakahara J, Tomita T, Iwatsubo T, Kato S, Aiso S, Nishimoto I, Kouyama K.
    Eur J Neurosci; 2004 May 24; 19(10):2826-38. PubMed ID: 15147316
    [Abstract] [Full Text] [Related]

  • 12. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
    Melnikova T, Savonenko A, Wang Q, Liang X, Hand T, Wu L, Kaufmann WE, Vehmas A, Andreasson KI.
    Neuroscience; 2006 Sep 01; 141(3):1149-62. PubMed ID: 16753269
    [Abstract] [Full Text] [Related]

  • 13. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice.
    Knobloch M, Konietzko U, Krebs DC, Nitsch RM.
    Neurobiol Aging; 2007 Sep 01; 28(9):1297-306. PubMed ID: 16876915
    [Abstract] [Full Text] [Related]

  • 14. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.
    Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O.
    Ann Neurol; 2004 Jun 01; 55(6):801-14. PubMed ID: 15174014
    [Abstract] [Full Text] [Related]

  • 15. Aberrant expressions of pathogenic phenotype in Alzheimer's diseased transgenic mice carrying NSE-controlled APPsw.
    Hwang DY, Cho JS, Lee SH, Chae KR, Lim HJ, Min SH, Seo SJ, Song YS, Song CW, Paik SG, Sheen YY, Kim YK.
    Exp Neurol; 2004 Mar 01; 186(1):20-32. PubMed ID: 14980807
    [Abstract] [Full Text] [Related]

  • 16. Mice expressing the Swedish APP mutation on a 129 genetic background demonstrate consistent behavioral deficits and pathological markers of Alzheimer's disease.
    Rustay NR, Cronin EA, Curzon P, Markosyan S, Bitner RS, Ellis TA, Waring JF, Decker MW, Rueter LE, Browman KE.
    Brain Res; 2010 Jan 22; 1311():136-47. PubMed ID: 19944081
    [Abstract] [Full Text] [Related]

  • 17. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?
    Götz J, Ittner LM, Kins S.
    J Neurochem; 2006 Aug 22; 98(4):993-1006. PubMed ID: 16787410
    [Abstract] [Full Text] [Related]

  • 18. Age-progressing cognitive impairments and neuropathology in transgenic CRND8 mice.
    Hyde LA, Kazdoba TM, Grilli M, Lozza G, Brusa R, Zhang Q, Wong GT, McCool MF, Zhang L, Parker EM, Higgins GA.
    Behav Brain Res; 2005 May 28; 160(2):344-55. PubMed ID: 15863231
    [Abstract] [Full Text] [Related]

  • 19. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice.
    Ribé EM, Pérez M, Puig B, Gich I, Lim F, Cuadrado M, Sesma T, Catena S, Sánchez B, Nieto M, Gómez-Ramos P, Morán MA, Cabodevilla F, Samaranch L, Ortiz L, Pérez A, Ferrer I, Avila J, Gómez-Isla T.
    Neurobiol Dis; 2005 Dec 28; 20(3):814-22. PubMed ID: 16125396
    [Abstract] [Full Text] [Related]

  • 20. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
    Shin RW, Ogino K, Shimabuku A, Taki T, Nakashima H, Ishihara T, Kitamoto T.
    Acta Neuropathol; 2007 Jun 28; 113(6):627-36. PubMed ID: 17431643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.